Directorio

We are doing this study to find out if an investigational, non-stimulant drug called SPN-812 (the study drug, viloxazine extended-release capsules). The study drug is FDA-approved for children ages 6 and above. It is not approved for children younger than 6, so this study is being done to determine how well it works and how safe it is for preschool-aged children.

We are doing this study to find out if an experimental drug called mosunetuzumab (the study drug) is a safe and effective option for low burden follicular lymphoma. We want to know how well it works in comparison to rituximab, which is the standard drug used to treat people with this diagnosis.

The SYNCHRONICITY study is a test to compare two treatments for people with heart failure and a heart electrical problem called left bundle branch block. People in the study will be randomly chosen to get one of two devices: a new type called LBBAP or a regular type called CRT. First, they will have surgery to put in the device. Then, they will have checkups at 6 months, 12 months, and once a year for up to 5 years. At these visits, doctors will check the device, do heart tests, and ask how the person feels. The study wants to find out which device is safer and works better.

We are doing this study to help connect people with type 1 diabetes to research studies they may be eligible to join as participants.

We are doing this study to find out if an experimental drug called mezagitamab (the study drug) is a safe and effective option for people with chronic primary immune thrombocytopenia (ITP). We want to know if adding the study drug to someone's current treatment has any benefit.

We are doing this study to find out if children and young adults with high-grade gliomas who have specific genetic changes (mutations) have better outcomes when they are treated with drugs that "target" those genetic changes. We first need to collect detailed information about the genetic changes within participants' brain tumors. If someone's brain tumor has a targeted genetic change, they may be eligible to participate in a clinical trial with a drug that specifically targets those genetic changes.

In this study, people will take two medicines called ribociclib and everolimus for up to two years. Both medicines are taken by mouth every day in repeating monthly cycles. Ribociclib is taken for three weeks and then stopped for one week, while everolimus is taken the whole month. Participants will visit the doctor before starting the study and then about once every four weeks during treatment. They may have more visits if needed. At these visits, doctors will do tests such as blood work, heart tests, scans like MRI, and a spinal tap. Participants will also answer questions about how they feel and their quality of life during the study.